CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10078 |
|---|---|
| Brand Name | Cyramza |
| Generic Name | Ramucirumab |
| Tumour Type | Lung |
| Indication | Non-Small Cell Lung Cancer |
| Funding Request | For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after platinum-based chemotherapy in combination with docetaxel |
| Review Status | File-Closed Not Submitted |
| Pre Noc Submission | Yes |
| NOC Date | |
| Manufacturer | Eli Lilly Canada Inc. |
| Sponsor | Eli Lilly Canada Inc. |
| Clarification | The submitter notified pCODR that they will not be filing the submission. |
| Submission Date (Target Date) | |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline (target date based on target submission date) ‡ | |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.